A2M doesn't have a patent on the A2 protein itself, only the process it uses to determine that a cow only has the A2 protein. You can't patent the A2 protein.
This appears to be Nestle's attempt to enter the A2 market, which means they see legitimacy in the A2 concept and have their eye on A2M. If their product fails to gain any traction, they could simply buy A2M outright. They are a A$300b+ company, so a $15b acquisition would be relative chump change for them.
nestle - doing A2 infant formula, page-77
-
- There are more pages in this discussion • 165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.85 |
Change
-0.030(0.44%) |
Mkt cap ! $4.952B | |||
| Open | High | Low | Value | Volume |
| $6.93 | $6.98 | $6.83 | $10.27M | 1.490M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 18844 | $6.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.85 | 41602 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| A2M (ASX) Chart |